What Happened?
Aptos, CA-based Orbus-Therapeutics Appointed Bob Myers as Chief Executive Officer
About the Company
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
About the Person
Prior to founding Orbus Therapeutics, Inc., Bob was a co-founder of Jazz Pharmaceuticals, Inc., in 2003. At Jazz, he was a member of the Board of Directors, and most recently served as its President. He had management responsibility for sales, marketing, new product planning, product development, supply chain, project management and business development. From 2002 until 2003, he served as Executive Vice President, Pharmaceuticals at Exelixis. He previously held various positions with ALZA Corporation from 1992 to 2001, most recently as its Senior Vice President, Commercial Development. In this role, he was responsible for ALZA Corporation's corporate development, mergers and acquisitions, new product planning and corporate planning. He received BS and MS degrees from Stanford University and an MBA from the Stanford Graduate School of Business.
Info Source
Press Release
Short Profile